At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,351 enrolled
Drug / intervention
Spiolto® Respimat®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AERIAL®: Changes in Health and Functional Status in Patients With COPD During Therapy With Spiolto® Respimat®
In Brief
An observational study evaluating Spiolto® Respimat® for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 1,351 participants across 108 sites.
Detailed Summary
The objective of this NIS is to measure changes in health status including functional status using CCQ scores in COPD patients receiving treatment with Spiolto® Respimat® according to label after approximately 6 weeks in routine clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartMay 2017
Primary CompletionFeb 2019
Study CompletionMar 2019
TodayJul 2026
First PostedMay 24, 2017
Enrollment StartMay 26, 2017
Primary CompletionFeb 4, 2019
Study CompletionMar 24, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.1 years ago
Interventions
Spiolto® Respimat®drug
6 weeks